Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own ...

Tuesday's quarterly earnings release underscored the necessity for new revenue drivers. Although Pfizer exceeded analyst expectations with earnings of $0.87 per share against projections of $0.79, ...

Metsera, a New York-based biopharmaceutical start-up founded in 2022, is developing next-generation medicines for obesity and ...

Pfizer’s sales of its COVID-19 vaccine, Comirnaty, fell sharply by 25% in the U.S. during the third quarter of 2025, dropping ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Pfizer has increased its annual profit forecast and reported higher-than-expected profits for the third quarter amid a legal ...

Investing.com - Pfizer has raised and narrowed its annual diluted profit outlook to a range of $3.00 to $3.15 per share. The drugmaker had previously seen the figure at $2.90 to $3.10 a piece. It also ...